QQQ   303.46 (+1.28%)
AAPL   122.72 (+3.08%)
MSFT   216.21 (+1.00%)
FB   286.55 (+3.46%)
GOOGL   1,795.36 (+2.33%)
AMZN   3,220.08 (+1.64%)
TSLA   584.76 (+3.02%)
NVDA   535.60 (-0.09%)
BABA   264.01 (+0.25%)
CGC   26.65 (-7.47%)
GE   10.15 (-0.29%)
MU   67.08 (+4.67%)
AMD   92.63 (-0.03%)
T   28.87 (+0.42%)
NIO   45.36 (-10.23%)
F   9.24 (+1.76%)
ACB   9.75 (-16.52%)
NFLX   504.58 (+2.83%)
BA   213.01 (+1.09%)
GILD   61.12 (+0.74%)
DIS   149.44 (+0.97%)
QQQ   303.46 (+1.28%)
AAPL   122.72 (+3.08%)
MSFT   216.21 (+1.00%)
FB   286.55 (+3.46%)
GOOGL   1,795.36 (+2.33%)
AMZN   3,220.08 (+1.64%)
TSLA   584.76 (+3.02%)
NVDA   535.60 (-0.09%)
BABA   264.01 (+0.25%)
CGC   26.65 (-7.47%)
GE   10.15 (-0.29%)
MU   67.08 (+4.67%)
AMD   92.63 (-0.03%)
T   28.87 (+0.42%)
NIO   45.36 (-10.23%)
F   9.24 (+1.76%)
ACB   9.75 (-16.52%)
NFLX   504.58 (+2.83%)
BA   213.01 (+1.09%)
GILD   61.12 (+0.74%)
DIS   149.44 (+0.97%)
QQQ   303.46 (+1.28%)
AAPL   122.72 (+3.08%)
MSFT   216.21 (+1.00%)
FB   286.55 (+3.46%)
GOOGL   1,795.36 (+2.33%)
AMZN   3,220.08 (+1.64%)
TSLA   584.76 (+3.02%)
NVDA   535.60 (-0.09%)
BABA   264.01 (+0.25%)
CGC   26.65 (-7.47%)
GE   10.15 (-0.29%)
MU   67.08 (+4.67%)
AMD   92.63 (-0.03%)
T   28.87 (+0.42%)
NIO   45.36 (-10.23%)
F   9.24 (+1.76%)
ACB   9.75 (-16.52%)
NFLX   504.58 (+2.83%)
BA   213.01 (+1.09%)
GILD   61.12 (+0.74%)
DIS   149.44 (+0.97%)
QQQ   303.46 (+1.28%)
AAPL   122.72 (+3.08%)
MSFT   216.21 (+1.00%)
FB   286.55 (+3.46%)
GOOGL   1,795.36 (+2.33%)
AMZN   3,220.08 (+1.64%)
TSLA   584.76 (+3.02%)
NVDA   535.60 (-0.09%)
BABA   264.01 (+0.25%)
CGC   26.65 (-7.47%)
GE   10.15 (-0.29%)
MU   67.08 (+4.67%)
AMD   92.63 (-0.03%)
T   28.87 (+0.42%)
NIO   45.36 (-10.23%)
F   9.24 (+1.76%)
ACB   9.75 (-16.52%)
NFLX   504.58 (+2.83%)
BA   213.01 (+1.09%)
GILD   61.12 (+0.74%)
DIS   149.44 (+0.97%)
Log in
NASDAQ:EXAS

Exact Sciences Stock Forecast, Price & News

$123.23
+2.17 (+1.79 %)
(As of 12/1/2020 12:00 AM ET)
Add
Compare
Today's Range
$121.38
Now: $123.23
$126.64
50-Day Range
$99.61
MA: $116.24
$131.12
52-Week Range
$35.25
Now: $123.23
$141.90
Volume1.57 million shs
Average Volume1.99 million shs
Market Capitalization$18.54 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.87
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; and Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer. The company's pipeline products focuses on the research and development of enhancing Cologuard's performance characteristics, and blood or other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; Biocartis N.V.; and Hologic, Inc. Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.
Exact Sciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.4Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.56 out of 5 stars


Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:EXAS
CUSIP30063P10
Phone608-535-8815
Employees4,110

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$876.29 million
Book Value$15.54 per share

Profitability

Net Income$-83,990,000.00

Miscellaneous

Market Cap$18.54 billion
Next Earnings Date2/9/2021 (Estimated)
OptionableOptionable
$123.23
+2.17 (+1.79 %)
(As of 12/1/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive EXAS News and Ratings via Email

Sign-up to receive the latest news and ratings for EXAS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Exact Sciences (NASDAQ:EXAS) Frequently Asked Questions

How has Exact Sciences' stock price been impacted by COVID-19?

Exact Sciences' stock was trading at $57.82 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, EXAS stock has increased by 113.1% and is now trading at $123.23.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Exact Sciences?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exact Sciences in the last year. There are currently 3 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Exact Sciences
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Exact Sciences?

Wall Street analysts have given Exact Sciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Exact Sciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Exact Sciences' next earnings date?

Exact Sciences is scheduled to release its next quarterly earnings announcement on Tuesday, February 9th 2021.
View our earnings forecast for Exact Sciences
.

How were Exact Sciences' earnings last quarter?

Exact Sciences Co. (NASDAQ:EXAS) announced its quarterly earnings data on Sunday, November, 1st. The medical research company reported ($1.46) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.51) by $0.95. The medical research company earned $408.40 million during the quarter, compared to analyst estimates of $337.43 million. Exact Sciences had a negative return on equity of 11.71% and a negative net margin of 25.27%. The firm's revenue for the quarter was up 86.7% on a year-over-year basis. During the same quarter last year, the business posted ($0.31) earnings per share.
View Exact Sciences' earnings history
.

What price target have analysts set for EXAS?

15 brokers have issued 1-year price targets for Exact Sciences' shares. Their forecasts range from $70.00 to $160.00. On average, they expect Exact Sciences' share price to reach $127.40 in the next twelve months. This suggests a possible upside of 3.4% from the stock's current price.
View analysts' price targets for Exact Sciences
.

Who are some of Exact Sciences' key competitors?

What other stocks do shareholders of Exact Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Exact Sciences investors own include Novavax (NVAX), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), salesforce.com (CRM), PayPal (PYPL), Square (SQ), Advanced Micro Devices (AMD), The Walt Disney (DIS) and AbbVie (ABBV).

Who are Exact Sciences' key executives?

Exact Sciences' management team includes the following people:
  • Mr. Kevin T. Conroy, Chairman, Pres & CEO (Age 54, Pay $1.82M)
  • Mr. Jeffrey T. Elliott CFA, Chief Financial Officer (Age 42, Pay $701.77k)
  • Ms. Ana Hooker, Sr. VP of Operations (Age 54, Pay $627.49k)
  • Mr. D. Scott Coward, Chief Admin. Officer, Sr. VP, Gen. Counsel & Sec. (Age 55, Pay $741.87k)
  • Mr. Jake Orville, Sr. VP of Pipeline (Age 46, Pay $769.63k)
  • Mr. G. Bradley Cole, Gen. Mang. of Precision Oncology (Age 64, Pay $1.23M)
  • Mr. Gary Frings, Chief Information Officer
  • Dr. Scott C. Johnson Ph.D., Chief Science Officer and Sr. VP of R&D
  • Ms. Megan Jones, Associate Mang. of Investor Relations
  • Mr. Tim Caprez, Chief Compliance Counsel & VP

What is Exact Sciences' stock symbol?

Exact Sciences trades on the NASDAQ under the ticker symbol "EXAS."

Who are Exact Sciences' major shareholders?

Exact Sciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include William Blair Investment Management LLC (1.45%), Nuveen Asset Management LLC (0.75%), Natixis (0.74%), First Trust Advisors LP (0.62%), Factory Mutual Insurance Co. (0.51%) and Swiss National Bank (0.39%). Company insiders that own Exact Sciences stock include D Scott Coward, G Bradley Cole, Jacob A Orville, James Edward Doyle, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Mark Stenhouse, Scott C Johnson and Torsten Hoof.
View institutional ownership trends for Exact Sciences
.

Which institutional investors are selling Exact Sciences stock?

EXAS stock was sold by a variety of institutional investors in the last quarter, including Toronto Dominion Bank, Durable Capital Partners LP, Handelsbanken Fonder AB, Paloma Partners Management Co, ArrowMark Colorado Holdings LLC, Pictet & Cie Europe SA, New York State Common Retirement Fund, and Artemis Investment Management LLP. Company insiders that have sold Exact Sciences company stock in the last year include G Bradley Cole, Jacob A Orville, James Edward Doyle, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Mark Stenhouse, and Torsten Hoof.
View insider buying and selling activity for Exact Sciences
.

Which institutional investors are buying Exact Sciences stock?

EXAS stock was purchased by a variety of institutional investors in the last quarter, including Natixis, ARK Investment Management LLC, William Blair Investment Management LLC, Peregrine Capital Management LLC, Worldquant Millennium Advisors LLC, Wasatch Advisors Inc., Nikko Asset Management Americas Inc., and Factory Mutual Insurance Co..
View insider buying and selling activity for Exact Sciences
.

How do I buy shares of Exact Sciences?

Shares of EXAS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Exact Sciences' stock price today?

One share of EXAS stock can currently be purchased for approximately $123.23.

How big of a company is Exact Sciences?

Exact Sciences has a market capitalization of $18.54 billion and generates $876.29 million in revenue each year. The medical research company earns $-83,990,000.00 in net income (profit) each year or ($1.49) on an earnings per share basis. Exact Sciences employs 4,110 workers across the globe.

What is Exact Sciences' official website?

The official website for Exact Sciences is www.exactsciences.com.

How can I contact Exact Sciences?

Exact Sciences' mailing address is 5505 ENDEAVOR LANE, MADISON WI, 53719. The medical research company can be reached via phone at 608-535-8815 or via email at [email protected]

This page was last updated on 12/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.